VICTORIA, British Columbia--(BUSINESS WIRE)--
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has launched ALL INTM, an educational program for people living with lupus nephritis (LN). ALL IN is designed to raise awareness for LN and to support members of the LN community.
LN in an inflammation of the kidney caused by Systemic Lupus Erythematosus (SLE) and represents a serious progression of SLE. Though approximately three out of every five people with lupus will go on to develop LN, many people living with lupus are less familiar with LN and have a number of questions about how to manage their disease once it affects the kidneys.
“As the leader of a national patient-led organization, I commend Aurinia for having the vision to elevate awareness for lupus nephritis, one of many potential manifestations of SLE that is often misunderstood by those affected. Aurinia’s dedication to educate and empower individuals and loved ones impacted by lupus nephritis by providing essential information, resources and support, is commensurate with our mission to improve quality of life,” stated Kathleen A. Arntsen, President and CEO, Lupus and Allied Diseases Association.
ALLINforLupusNephritis.com, the first component of the ALL IN program, is a website that features educational information about LN, downloadable resources, helpful links, and personal stories and insights shared by people affected by LN. Visitors to the ALL IN website also have the opportunity to receive ongoing news and updates.
“We are committed to serving the needs of people with LN and their families, and upon receiving extensive feedback from members of the community, we conceptualized and built the ALL IN program—a centralized place where those affected by LN can access pertinent and timely information related to their condition,” said Brad Dickerson, General Manager, Americas.
About Lupus Nephritis (LN)
LN is an inflammation of the kidney caused by Systemic Lupus Erythematosus (SLE) and represents a serious progression of SLE. SLE is a chronic, complex and often disabling disorder and affects more than 500,000 people in the United States (mostly women). The disease is highly heterogeneous, affecting a wide range of organs & tissue systems. It is estimated that as many as 60 percent of all SLE patients will develop clinical LN requiring treatment. Unlike SLE, LN has straightforward disease outcomes (measuring proteinuria) where an early response correlates with long-term outcomes. In patients with LN, renal damage results in proteinuria and/or hematuria and a decrease in renal function as evidenced by reduced estimated glomerular filtration rate (eGFR), and increased serum creatinine levels. LN is debilitating and costly and if poorly controlled, LN can lead to permanent and irreversible tissue damage within the kidney, resulting in end-stage renal disease (ESRD), thus making LN a serious and potentially life-threatening condition.
Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), minimal change disease MCD and dry eye syndrome (DES). The company is headquartered in Victoria, BC and focuses its development efforts globally. For further information, see our website at www.auriniapharma.com.